Zoetis Inc. (ZTS) Sees Mixed Analyst Sentiment as Targets Are Trimmed

Group 1 - Zoetis Inc. (NYSE:ZTS) is recognized as one of the most profitable healthcare stocks to consider for investment, with a current price target of $130 set by Stifel Nicolaus, indicating a potential upside of 4.91% [1] - Piper Sandler downgraded Zoetis from Overweight to Neutral, reducing the price target from $190 to $135, citing concerns over the company's innovation timeline and projecting a potential "innovation air pocket" lasting one to two years [2] - Morgan Stanley also adjusted its price target for Zoetis, lowering it from $175 to $160 while maintaining an Overweight rating, suggesting a favorable environment for healthcare companies in 2026 despite current challenges in managed care stocks [3] Group 2 - Zoetis Inc. is a New Jersey-based company established in 1950, specializing in a range of health products including animal health medicines, vaccines, biodevices, and genetic tests, with a goal to become the most valuable animal health company [4]